CA
NZ
UK
AU
IND
US
● At barely a dime a share, the stock sits firmly in penny-stock territory.
● No trial result, regulatory decision or financing has been tied to the move.
Charles River Laboratories International, Inc. (NYSE:CRL) has a market capitalisation of about $14.4 billion. Following a September 24 Investor Day, several analysts raised targets, and UBS resumed coverage at Buy with a $357 target. Investors may be assessing whether the long-range targets are credible.
CervoMed (NASDAQ:CRVO), a clinical-stage company developing neflamapimod for neurodegenerative conditions, has a crowded calendar of scientific events through the end of 2026. The International Society for Frontotemporal Dementia (ISFTD) conference ran from October 8 to 11, where the company planned to present 12-week biomarker …
● The heaviest selling that day was in AI and semiconductor stocks, not healthcare.
● The chip selloff does not explain a drop in this eye-health company.
Celularity Inc. (NASDAQ:CELU), a regenerative and cellular medicine company based in New Jersey, has had a busy period of corporate announcements: a private placement as part of a planned recapitalization, new board appointments, manufacturing and wellness partnerships, and a Nasdaq notice over delayed quarterly …
AMN Healthcare Services Inc (NYSE:AMN) has been attracting fresh analyst commentary as investors assess a stronger-than-expected outlook for the healthcare staffing market. The company has a market capitalisation of about $1.41 billion, and several brokers have lifted price targets in recent weeks, including BMO …
Adlai Nortye Group Ltd. (NASDAQ:ANL), a clinical-stage oncology company, has had a busy autumn, dosing the first patient in a new antibody-drug conjugate trial and strengthening its cash position through two private placements earlier in the year. The company has a market capitalisation of …
● A semiconductor-led selloff pushed investors toward value, energy and defensive healthcare.
Please wait processing your request...